Introduction: HIV resistance to antiretroviral is currently a global concern, and requires increased surveillance in a context of widespread ARV treatment. Objective: To evaluate early warning indicators of HIV resistance to ARVs in the Hospital of Tivaouane (Senegal) where viral load was not routinely available. Methods: This is a cross-sectional retrospective study from 2008-2016. The extraction tool (May 2010 version) was used to analyze the EWI. Results: We collected 360 HIV positive patients followed on average for 3.57 years ± 3.02. 2009, 2010 and 2012 recorded 100% ARV prescribing rates. Throughout the study period, the percentage of patients lost to follow-up during the first 12 months of treatment was less than 20%. Virtually, all patients were still under primary ARVT over 12-month treatment. All patients (100%) withdrew their ARV drugs on time. No stock storage regarding various classes of ARVs was noted during the study period. Conclusion: At the end of this study we recommend to maintain regular follow-up of EWI, and combine it with the achievement of viral load.
is not yet effective, due to some technical requirements that are generally to be considered in monitoring patients, plus problems connected to the collect and transfer of samples to agreed laboratories in the capital [2] . The increased use of HIV treatment with ARVs in low-and middle-income countries is seen as a factor that has led to the resistance to some kinds of treatment.
It is in this context that we conducted this study in the Hospital of Tivaouane.
The management and prescription of ARVs started from 2008 until 2017, the viral load as well as simplified alternative methods such as DBS for outlying areas was not routinely available, thus not allowing an optimal surveillance of therapeutic failures and of the resistance [3] . The objectives were:
• Evaluation of early warning indicators of resistance to HIV in this hospital from 2008 to 2016.
• Making recommendations for the prevention of resistance to ARVs.
Methology
Our study was carried on over the 8-year period ( from those who were previously prescribed an appropriate fist-line ARVT.  The target is 100%.
• EWI 2: Patients lost to follow-up during the first 12 months: this is the percentage among patients starting ARVT in the site during a selected period, from those lost to follow-up within 12 months after the beginning of the treatment.  The target is less 20%.
• EWI 3a: Patients receiving first-line ARVT over 12 months (retention indicator): this is the percentage of patients starting ARVT in the site during a selected period from those who continue to follow an appropriate first intention ARVT 12 month later.  The recommended target is greater than or equal to 70%.
• EWI 4a: Withdrawal of ARV drugs on time: this is the percentage of patients withdrawing drugs in a selected month (denominator month) from those who have withdrawn on time prescribed ARV drugs within the next 2 months.  Target is greater than 90%.
• EWI 6: Steady delivery of ARVs: this is the percentage of the current month of a given year during which no stock shortage of various classes of ARVs occurred.  The target is 90%.
The data entry and analysis were carried out using Microsoft Excel 2016 software. The averages and percentages were compared using the chi2 test. Any difference below 0.05 was considered to be statistically significant.
For the calculation of EWIs, data entry and analysis were carried out using the EWI Extraction.
Tool developed by WHO (May 2010 version) [4] .
Results

General Characteristics of PLHIV Followed in Tivaouane
From 2008 to 2016, 360 patients living with HIV were followed in the Hospital of Tivaouane. Their general characteristics are summarized in Table 1 .
Early Warning Indicators of Resistance to HIV
• IAP1: ARVT prescribing practices (Prescribing indicator)
During the follow-up, we observed a variation of prescribing indicators (Table 2 ).
• IPA 2: Patients lost to follow-up during the first 12 years of ART (Lost-to-follow-up indicator):
From 2008 to 2016, approximately 10% of patients were considered to be lost to follow-up over 12 months. This rate will drop over M24 and M36, and then increase over M60. Nevertheless, it remained below the target of less than 20% (see Table 3 ).
• IPA 3a: Patients on appropriate first-line ART over 12 months (retention indicator).
Among patients under first-line ART, more than 90% were still under this treatment after follow-up over 12 months (see Table 4 ). The recommended target is greater than or equal to 70%.
• EWI 4a: Withdrawing ARV drugs within indicating deadlines for this purpose. 
Discussion
This study, on patients infected by HIV followed-up in the Hospital of Tivaouane from January 2008 to December 2016, allowed us to better apprehend their socio-demographic, clinic, para-clinical and progressive characteristics;
and estimate EWIs of the resistance in this caregiving center at a decentralized level.
Results from the exploitation of data give rise to the following feedback: • General characteristics of the population of the study From 2008 to 2016, PLVIH have been followed in our structure; epidemiologically, our patients show (gender, middle-age, occupation, marital status) the same characteristics as those followed-up within other structures in Senegal [5] [6] [7] and in Sub-Saharan Africa [8] -Stock storage.
EWI Characteristics
Most of the studies on this theme are focused on several sites, which have not been the case in ours, which is focused on a single site, but this provides us an outline at local level.
Prescription Practices (EWI1)
Only the years 2009, 2010 and 2012 recorded 100% rates which were the target.
This could be due to various changes to national guidelines over the study period regarding first-line protocols. Such changes were due either to a lack or withdrawal of some molecules, or to the sale of new ARVs, or to the standardization of protocols in relation to international standards.
Nevertheless, the threshold is higher than the one found in the work achieved 
Those Lost to Follow in the First 12 Months of Antiretroviral Treatment (EWI2)
In Senegal, the estimate at national level for retention regarding care showed that 75.7% of adults were kept after 12 months of treatment [2] . In our documentation, we recorded about 10% of lost to follow-up over 12, or a retention rate of 90%. Such figure is similar to that found in a study conducted in the Fann's Infectious Diseases Department, a reference Department as part of caregiving for PLHIV where it was 11.1% [9] . It is significantly lower than that found in Côte d'Ivoire where a total of 33% of patients were lost to follow-up during the first 12 months of antiretroviral treatment. However, it should be noted that, 20% of sites had less than 20% of lost to follow-up patients [10] .
However, in Namibia, the retention rate was 79% after 12 months for adults, and 82% for pediatrics [11] . In Vietnam, it was 81.2% among adults, and 84.4% among children [12] . However, it should be noted that, in this latest study, retention regarding care rates between main sites and corner sites was similar for adults and pediatrics.
This finding is somewhat amazing, as decentralized sites can be expected to be better in keeping treated patients due to their convenience and reduced size. For example, Chan et al. demonstrated that patients treated in decentralized health centers in Malawi were 60% less likely to be lost to follow-up for the first 10 months of care [13] . However, a similar study conducted in Kenya showed that, patients in a primary health care facility were less likely to be lost to follow-up than those enrolled in a secondary health facility. Distance can also be a curb [14] . Maru showed that, with a statistically significant difference, patients whose residence was distant stopped their follow-up more easily [15] .
Percentage of Patients Kept under First-Line Treatment over 12 Months (EWI3a)
Among patients under first-line ARVT, more than 90% were still under this treatment after 12-month follow-up. In Côte d'Ivoire, 51% of patients are still under appropriate first-line treatment over 12 months [10] . According to the 2016 EWI WHO report, 73.5% of individuals out of 7,062 clinics in 50 countries during the 2004-2014 periods were kept in care facilities 12 months after initiation of ARVT [16] . To keep adequate suppression of virus replication, the ARV treatment adherence level should be greater than 90%. The failure to comply with this results in the emergence of virus resistance causing therapeutic failure. The World Health Organization recommends second-line treatment in the event of failure of first-line treatment [16] [17].
Withdrawing Drugs on Time (EWI4a)
This is an important measure of the adherence of the patient linked with HIV 
Regular Delivery of ARVs (EWI6)
There was no ARV rupture during our study period unlike the (Kouadio J Y) study where only one site did not experience antiretroviral ruptures over the 12 months [10] . According to the 2016 Global Report on early warning indicators, 35.7% of clinics reported at least one stock, out of 1703 clinics in 35 countries [16] . Stocks in Namibia were due to poor inventory management practices, constraints related to space for storage and expiring ARVs, which resulted in unusable ARVs on sites.
Namibia has been working on strengthening supervision by regional pharmacists to ensure a good forecast of drugs, supply and distribution [11] .
Conclusion
The results are definitely encouraging, but there are some shortcomings, particularly in terms of good practice regarding prescriptions and retention. We advocate a continuous update for physicians in relation to national recommendations concerning ARV treatment that is to be strictly observed, and the establishment of a formal and efficient active search system for the lost to follow-up patients, associating the medical staff, social works and families of patients. In addition, such results should be combined with the viral load now available to better assess the impact and importance of these resistance early warning indicators.
